Sanofi-Aventis

4Q Revenues: $10.1 billion (+3%)

4Q Earnings: $2.3 billion (+14%)

FY Revenues: $39.1 billion (-2%)

FY Earnings: $10.2 billion (+3%)

Comments: Pharmaceutical sales were up 3% in the quarter and for the year to $9.1 billion and $35.1 billion, respectively. Lovenox sales were $1.1 billion in the quarter (+8%) and $3.9 billion for the year (+11%). Plavix sales were $936.5 million in the quarter (+10%) and $3.7 billion for the year (+11%). Lantus sales were $1.0 billion in the quarter (+25%) and $3.5 billion for the year (+30%). Taxotere sales were $767.7 million in the quarter (+12%) and $2.9 billion for the year (+13%). Eloxatin sales were down 5% in the quarter to $503.7 million and down 6% for the year to $1.9 billion. R&D expenses were $1.9 billion in the quarter (+3%) and $6.5 billion for the year (+1%). Costs from the discontinuation of programs (primarily Acomplia) had a negative effect of approximately one percent.